阿昔洛韦联合地塞米松治疗单纯疱疹病毒性脑炎的实验研究

摘要

Objective To investigate the efficacy and mechanism of acyclovir combined with dexamethasone for the treatment of herpes simplex virus encephalitis in mice.Method BALB/c mice were randomized into normal control group,model group,acyclovir monotherapy group and acyclovir combined with dexamethasone treatment group.Since the first day after modeling,mice in the acyclovir group and combined treatment group administered acyclovir by garage,normal control group and model control group received normal saline,since the third day after modeling,the combined treatment group given dexamethasone by intraperitoneal injection,other groups received saline intraperitoneally.The administration continued until the seventh day after modeling.The neurological symptom score and protein expression of nuclear transcription factor-κB and tumor necrosis factor-α were measured on the third,fifth and seventh day after modeling,the cumulative probability of mice survival were analyzed for 12 days.Results 7 days after modeling,neurological symptoms score of model group was highest of all,that of the combined treatment group was the lowest,the acyclovir group was in the middle,there was significant differences (P ＜ 0.05) between any two groups.12 days after modeling,all the mice in the model group died,survival rate of combined treatment group was significantly higher than that of acyclovir group.7 days after modeling,the protein expression level of nuclear transcription factor-κB and tumor necrosis factor-α of the model group were significantly higher than the normal control group,that of the acyclovir group and combined treatment group were significantly decreased,and there was statistically significant differences (P ＜ 0.05) between groups.Conclusion Acyclovir combined with dexamethasone in the treatment of mice with herpes simplex virus encephalitis could exhibited better effect than acyclovir monotherapy.%目的 探讨阿昔洛韦联合地塞米松治疗小鼠单纯疱疹病毒性脑炎的疗效及作用机制.方法 BALB/c小鼠随机分为正常对照组、模型对照组、阿昔洛韦单药治疗组及阿昔洛韦联合地塞米松治疗组,阿昔洛韦组和联合治疗组小鼠给予阿昔洛韦灌胃,正常对照组和模型对照组给予生理盐水灌胃;建模后第3天,联合治疗组给予地塞米松腹腔注射,其他各组给予生理盐水腹腔注射,连续给药至建模后第7天.对各组小鼠进行神经症状评分并测定小鼠脑组织中核转录因子-κB及肿瘤坏死因子-α的蛋白表达,连续12 d观察各组小鼠进行生存分析研究.结果 建模7天后,模型组小鼠神经症状评分最高,联合治疗组神经症状评分最低,阿昔洛韦组介于两者之间,组间差异有统计学意义(P＜0.05);模型组小鼠全部死亡,联合治疗组生存率明显高于阿昔洛韦组;模型对照组小鼠脑组织中核转录因子-κB及肿瘤坏死因子-α表达量明显高于正常对照组,阿昔洛韦组及联合治疗组均明显下降,且组间差异有统计学意义(P＜0.05).结论 阿昔洛韦联合地塞米松治疗小鼠单纯疱疹病毒性脑炎,较阿昔洛韦单药治疗效果明显,表现为小鼠生存率显著提高,神经症状减轻,及在蛋白水平上明显抑制单纯疱疹病毒性脑炎小鼠脑组织中核转录因子-κB及肿瘤坏死因子-α的过表达.